OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV.

Curr Issues Mol Biol · 2026 · PMC13204828 · PMID 42193057

Europe PMC DOI

hedged sentences

0.0810

closest p · 1.6× alpha

0.0860

boldest claim

The sentences

did not reach statistical significancep = 0.081so close (0.05 < p ≤ 0.1)

58.7 ± 14.5 years), though this did not reach statistical significance ( p = 0.081).

also in 57,071 other papers

at the threshold of significancep = 0.086so close (0.05 < p ≤ 0.1)

Although this trend was at the threshold of significance ( p = 0.086), it prompts intriguing questions regarding hepatic remodeling.

also in 43 other papers

borderline significancep = 0.086so close (0.05 < p ≤ 0.1)

Notably, non-cirrhotic status was more prevalent among hyperbilirubinemic patients (91.7%) compared to the stable group (64.1%), demonstrating borderline significance ( p = 0.086). 3.2.

also in 2,668 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

OATP1B3 c.699G&gt;A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV.

The sentences

OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV.